Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (ផ្សារហ៊ុន NASDAQ: BCRX) reported a setback on the early-stage BCX10013 study.
The company noted recent dose-related observations in an ongoing BCX10013 nonclinical study would delay the clinical program.
BioCryst planned to advance BCX10013 into patient studies in mid-2023, including in patients with paroxysmal nocturnal hemoglobinuria (PNH), to evaluate once-daily dosing.
In January, the company announced initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers.
It showed rapid, sustained, and >97 percent suppression of the complement system’s alternative pathway (AP) 24 hours following a single 110 mg dose and that BCX10013 has been safe and generally well-tolerated at all doses studied to date.
ត្រូវការ។ writes that they believe the sell-off was overdone and that BCRX’s 25% YTD decline brought its shares to the level that fails to adequately capture Orladeyo’s sales (2023 sales guidance of ≥$320 million, +27%Y/Y) and growth trajectory.
The analyst upgraded the stock to Buy from Hold with a price target of $14.
The analyst expects Orladeyo can attain peak sales of $700 million, given that competition from another oral HAE prophylactic is unlikely for at least 5-7 years.
BCRX’s OpEx spending is high, but the company is well-funded, with a cash balance of $443.9 million. The BCX10013 setback may prompt R&D spending cuts that accelerate the progression to break even, potentially as early as 2024.
សកម្មភាពតម្លៃ: BCRX shares are up 12.33% at $9.70 on the last check Wednesday.
Latest Ratings for BCRX
កាលបរិច្ឆេទ | ក្រុមហ៊ុន | សកម្មភាព | ពី | ទៅ |
---|---|---|---|---|
ថ្ងៃ2021 ខែធ្នូ ឆ្នាំ | អូផិនហឺមឺរ។ | ចាប់ផ្តើមគ្របដណ្តប់លើ | គំរូល្អជាង | |
ថ្ងៃី2021 ខែវិច្ឆិកា ឆ្នាំXNUMX | មូលធន RBC | រក្សា | Sector Perform | |
ថ្ងៃី2021 ខែវិច្ឆិកា ឆ្នាំXNUMX | ក្រុមហ៊ុន Barclays | រក្សា | លើសទម្ងន់ |
View More Analyst Ratings for BCRX
កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.
អត្ថបទនេះ អ្នកវិភាគមើលឃើញពីឱកាសនៃការចូលដ៏គួរឱ្យទាក់ទាញ បន្ទាប់ពីការធ្លាក់ចុះនៃបំពង់បង្ហូរប្រេង BioCryst ដើមដំបូងបានបង្ហាញខ្លួន benzinga.com
.
© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សារសិទ្ធគ្រប់យ៉ាង។
Source: https://finance.yahoo.com/news/analyst-sees-attractive-entry-opportunity-193122895.html